ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010.
 PMID: 22448246       2012       PloS one
Table: T215D


  HIV-1 subtype D infections among Caucasians from Northwestern Poland--phylogenetic and clinical analysis.
 PMID: 22359615       2012       PloS one
Abstract: Baseline drug resistance to nucleoside reverse transcriptase inhibitors was observed in 54.5% of cases (mutations: M41L, K103N, T215S/D) with evidence of clustering, no baseline integrase or protease resistance and infrequent non-R5 tropism (13.6%).
Table: T215D


  Emerging transmitted drug resistance in treatment-naive human immunodeficiency virus-1 CRF06_cpx-infected patients in Estonia.
 PMID: 20964489       2011       Scandinavian journal of infectious diseases
Abstract: A total of 2.8% of sequences harboured mutations indicating nucleoside/nucleotide reverse transcriptase inhibitor resistance (M41L, M184V, M184I, T215C and T215D), 2.1% non-nucleoside reverse transcriptase inhibitor resistance (K103N, P225H) and 2.8% protease inhibitor resistance (M46I, L90M).


  Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
 PMID: 21765365       2011       Journal of acquired immune deficiency syndromes (1999)
Result: The T215 codon was indeterminate in plasma virus by OLA, suggestive of a transitional mutation, which by consensus sequencing was T215D.


  Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.
 PMID: 22046345       2011       PloS one
Result: Both specimens harboured mutations F53L and L90M at PR and M41L, K103N, L210W and T215D at RT.


  Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.
 PMID: 20628644       2010       PloS one
Introduction: We also studied so called T215 reversion mutations (T215A/C/D/E/G/H/I/L/N/S/V).
Result: We also investigated the levels of preexisting T215 reversion mutations (T215A/C/D/E/G/H/I/L/N/S/V) and found that four of five patients had preexisting levels of T215A and/or T215I that ranged from 0.05% to 0.11% (Table 3), whereas we did not detect any of the other 215 reversion mutations.
Table: T215C/D


  Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.
 PMID: 19704170       2009       Antiviral therapy
Result: Seven recently infected subjects harbored T215C or T215D revertant mutations, which represent the first back-mutation away from T215Y.


  HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naive patients from Central West Brazil.
 PMID: 19682948       2009       Journal of clinical virology
Abstract: T215D/S revertant mutations were identified in 4/97 patients.


  HIV-1 transmission cluster with T215D revertant mutation among newly diagnosed patients from the Basque Country, Spain.
 PMID: 19282784       2009       Journal of acquired immune deficiency syndromes (1999)
Abstract: One of these comprised 14 individuals, 12 of them MSM, with the T215D revertan mutation.


  Primary drug resistance in antiretroviral-naive injection drug users.
 PMID: 19111493       2009       International journal of infectious diseases
Abstract: RESULTS: Genotypic drug resistance was uncommon, and was only identified in six (4.7%) cases, all in the RT gene (L100I, K103N, Y181C, M184V, Y188L, and T215D).



Browser Board

 Co-occurred Entities




   Filtrator